Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
894.1 USD | +1.23% | -0.95% | +1.52% |
26/04 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
26/04 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.52% | 95.28B | |
-2.25% | 103B | |
+3.00% | 22.15B | |
-16.00% | 21.02B | |
-8.38% | 18.15B | |
-41.01% | 16.73B | |
-13.87% | 16.05B | |
+4.01% | 13.68B | |
+34.85% | 12.17B | |
-23.12% | 8.24B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals' Revenue Slides, Still Tops Street Views as R&D Spending Picks Up